Tests eptinezumab with usual care for migraine in emergency department patients
Tests eptinezumab alongside usual care in adults with migraine treated in emergency departments.
Plain-language title generated from the registry record
Registry title: Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
Key facts
- Where
- New Westminster and Surrey, CanadaSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 75 years old?
Source: NCT06428838, who can take part
Where in Canada
- Royal Columbian HospitalNew Westminster, CanadaNo longer taking part
- Surrey Memorial HospitalSurrey, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dr George Medvedev
- Trial code
- NCT06428838
- Record updated
- 30 September 2026
- Original description
The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED.Read full original descriptionShow less
Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study)
The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED.
Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptinezumab can rapidly interrupt the migraine process, potentially also preventing migraine from coming back in the short term.
Most patients with a diagnosis of migraine have no access to preventative therapies. This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack. Administering this medication in the ED may stop the attack more effectively compared to current therapies.
This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED. The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED, what other medications they might need alongside eptinezumab, and how they feel overall.
Inclusion: Adults between the ages of 19-75 with a history of migraines, as established at the time of presentation to the ED or known from the patient's chart; Presenting to the emergency department with a migraine that meets ICHD-3 migraine headache criteria; Provided signed informed consent; Sufficient literacy and cognitive capacity to understand and complete patient self-rated questionnaires in English.
Exclusion: Currently enrolled in another investigational drug trial; Currently on anti-CGRP therapy with monoclonal antibodies; Secondary headaches caused by an injury or underlying illness, such as a concussion, bleeding in the brain, an infection or a brain tumor; Current or history of severe cardiovascular disease or renal dysfunction; A systemic condition in the stage of active treatment (vasculitis, etc.); Any other condition which, in the opinion of the Investigator, would exclude the participant due to reasons of safety or data integrity; Hypersensitivity to the active substance or to any of the excipients; Pregnant or at risk of becoming pregnant (absent contraception); Dosed with eptinezumab within the past 3 months; Currently involved in active litigation.